KR20190016507A - TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체 - Google Patents

TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체 Download PDF

Info

Publication number
KR20190016507A
KR20190016507A KR1020187035676A KR20187035676A KR20190016507A KR 20190016507 A KR20190016507 A KR 20190016507A KR 1020187035676 A KR1020187035676 A KR 1020187035676A KR 20187035676 A KR20187035676 A KR 20187035676A KR 20190016507 A KR20190016507 A KR 20190016507A
Authority
KR
South Korea
Prior art keywords
ser
leu
seq
sequence
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020187035676A
Other languages
English (en)
Korean (ko)
Inventor
엘세 마리트 인데르베르그
구스타프 가우데르낙
세바스첸 왈실리
군나르 크발하임
Original Assignee
오슬로 유니버시테시케후스 에이치에프
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오슬로 유니버시테시케후스 에이치에프 filed Critical 오슬로 유니버시테시케후스 에이치에프
Publication of KR20190016507A publication Critical patent/KR20190016507A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4225Growth factors
    • A61K40/4229Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4271Melanoma antigens
    • A61K40/4272Melan-A/MART
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/495Transforming growth factor [TGF]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50Colon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
KR1020187035676A 2016-05-09 2017-05-09 TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체 Abandoned KR20190016507A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608052.5A GB201608052D0 (en) 2016-05-09 2016-05-09 T-cell receptors which recognise frameshift mutants of TGF-beta RII
GB1608052.5 2016-05-09
PCT/EP2017/061087 WO2017194555A1 (en) 2016-05-09 2017-05-09 T-CELL RECEPTORS WHICH RECOGNISE FRAMESHIFT MUTANTS OF TGFßRII

Publications (1)

Publication Number Publication Date
KR20190016507A true KR20190016507A (ko) 2019-02-18

Family

ID=56297359

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187035676A Abandoned KR20190016507A (ko) 2016-05-09 2017-05-09 TGFβRII의 프레임시프트 돌연변이체를 인식하는 T-세포 수용체

Country Status (13)

Country Link
US (1) US20190336529A1 (enExample)
EP (1) EP3455249B1 (enExample)
JP (1) JP2019517790A (enExample)
KR (1) KR20190016507A (enExample)
CN (1) CN109328196B (enExample)
AU (1) AU2017261684A1 (enExample)
CA (1) CA3024555A1 (enExample)
EA (1) EA201892217A1 (enExample)
GB (1) GB201608052D0 (enExample)
IL (1) IL262873A (enExample)
MX (1) MX2018013581A (enExample)
SG (1) SG11201809716VA (enExample)
WO (1) WO2017194555A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10724043B2 (en) * 2016-10-06 2020-07-28 Nantbio, Inc. Multi-pulse transfection methods and cells
WO2018104473A1 (en) 2016-12-07 2018-06-14 Oslo Universitetssykehus Hf Compositions and methods for cell therapy
GB201713078D0 (en) * 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3692058A1 (en) * 2017-10-06 2020-08-12 Oslo Universitetssykehus HF Chimeric antigen receptors
SG11202102903QA (en) 2018-09-21 2021-04-29 Xlifesc Ltd High affinity t cell receptor for recognizing afp antigen
US20220193137A1 (en) * 2019-04-04 2022-06-23 Umc Utrecht Holding B.V. Modified immune receptor constructs
GB201907663D0 (en) 2019-05-30 2019-07-17 Ab Mavatar Method for diagnosing colorectal cancer
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
WO2023050063A1 (zh) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 一种识别hla-a*02:01/e629-38的tcr及其应用
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
WO2024263818A2 (en) * 2023-06-20 2024-12-26 Immunova Therapeutics Llc Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains
WO2024260454A1 (zh) * 2023-06-21 2024-12-26 北京可瑞生物科技有限公司 经修饰的tcr恒定区及其在tcr融合蛋白中的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315238B1 (no) * 1998-05-08 2003-08-04 Gemvax As Peptider som stammer fra leserammeforskyvingsmutasjoner i TBF<beta>II- eller BAX-genet, og farmasöytiske sammensetninger inneholdende disse,nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slikenukleinsy
FR2779432A1 (fr) * 1998-06-08 1999-12-03 Transgene Sa Sequence nucleique du recepteur rii du tgfb, peptide code, et utilisations
AU2010277629B2 (en) * 2009-07-29 2016-05-19 Glaxo Group Limited Anti - TGF - beta receptor type II single domain antibodies
AU2012261933B2 (en) * 2011-06-03 2017-06-15 Xoma Technology Ltd. Antibodies specific for TGF-beta
US9764037B2 (en) * 2012-12-06 2017-09-19 Victoria Link Limited Conjugate compounds
WO2015169853A1 (en) * 2014-05-06 2015-11-12 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading
WO2015189267A2 (en) * 2014-06-10 2015-12-17 Universitetet I Oslo Engineered invariant chain molecule for improved mhc class i loading

Also Published As

Publication number Publication date
EP3455249A1 (en) 2019-03-20
WO2017194555A1 (en) 2017-11-16
GB201608052D0 (en) 2016-06-22
CA3024555A1 (en) 2017-11-16
EA201892217A1 (ru) 2019-08-30
US20190336529A1 (en) 2019-11-07
EP3455249B1 (en) 2023-05-03
MX2018013581A (es) 2019-07-04
JP2019517790A (ja) 2019-06-27
CN109328196B (zh) 2022-11-01
AU2017261684A1 (en) 2018-12-13
CN109328196A (zh) 2019-02-12
IL262873A (en) 2019-01-31
SG11201809716VA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CN109328196B (zh) 识别TGFβRII的移码突变体的T细胞受体
TWI727182B (zh) 新型t細胞受體及其免疫治療
AU2009317161B2 (en) High affinity T cell receptor and use thereof
KR20190086562A (ko) T 세포 수용체 및 이를 사용하는 면역 요법
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2019525898A (ja) ヒト白血球抗原拘束ガンマデルタt細胞受容体及びその使用方法
JP2018508219A (ja) 免疫調節性融合タンパク質およびその使用
ES2749903T3 (es) Proteína quimérica
EP2041171A2 (en) Epitope-tag for surface-expressed proteins and uses thereof
WO2016184592A1 (en) T cell receptor with specificity for myeloperoxidase peptide and uses thereof
Matsuzaki et al. A rare population of tumor antigen-specific CD4+ CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells
JP2023525049A (ja) ナチュラルキラー細胞を標的とするキメラ抗原受容体(car)
CN115768464A (zh) 产生工程化记忆样nk细胞及其组合物的方法
US20170354681A1 (en) T cell-based immunotherapeutics
CN110272482B (zh) 识别prame抗原短肽的t细胞受体
TWI843716B (zh) hTERT特異性結合分子
TW202144401A (zh) 一種辨識afp的t細胞受體
CN108290940A (zh) Tcr及其用途
EA042909B1 (ru) Т-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, КОТОРЫЕ РАСПОЗНАЮТ МУТАНТНЫЕ ВАРИАНТЫ СО СДВИГОМ РАМКИ СЧИТЫВАНИЯ TGFβRII
KR20240099260A (ko) 변형된 결합 단백질 및 이의 치료적 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181207

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200429

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220314

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220825

PC1904 Unpaid initial registration fee